The India Cements (INDIACEM) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
1 Sep, 2025Executive summary
Audited standalone and consolidated financial results for the quarter and year ended 31 March 2025 were approved, with statutory auditors issuing unmodified opinions for both sets of results.
The company operates primarily in the cement segment, with no reportable segments other than cement.
During the quarter, several subsidiaries and associates ceased to be part of the group, and the board approved the amalgamation of four wholly owned subsidiaries, pending regulatory approval.
Financial highlights
Standalone revenue from operations for Q4 FY25 was ₹1,197.13 crore, up from ₹903.16 crore in Q3 FY25, but down from ₹1,245.38 crore in Q4 FY24.
Standalone net loss for Q4 FY25 was ₹75.66 crore, compared to a net loss of ₹428.84 crore in Q3 FY25 and ₹29.33 crore in Q4 FY24.
For the full year FY25, standalone revenue was ₹4,088.47 crore (down from ₹4,942.43 crore in FY24), with a net loss of ₹667.56 crore (wider than the ₹202.52 crore loss in FY24).
Consolidated revenue for FY25 was ₹4,148.78 crore, with a consolidated net loss of ₹143.68 crore, compared to a net loss of ₹227.34 crore in FY24.
Outlook and guidance
The board approved the amalgamation of four wholly owned subsidiaries, with the appointed date as 1 January 2025; the financial results do not include the impact of this amalgamation as it is subject to regulatory approvals.
Latest events from The India Cements
- Sales and EBITDA improved as expansion, brand transition, and restructuring progressed.INDIACEM
Q2 25/263 Feb 2026 - Sales up 25% YoY, revenue higher, but net losses persist amid expansion and legal risks.INDIACEM
Q3 25/262 Feb 2026 - Sales volume up to 11.6% YoY, EBITDA/ton improved, losses narrowed, double-digit growth targeted.INDIACEM
Q1 25/266 Jan 2026 - Profitability returned in Q1 FY25 on an exceptional gain, with major stake sale to UltraTech Cement.INDIACEM
Q1 24/251 Sep 2025 - Losses widened on lower revenue, with major asset sales and a pending UltraTech acquisition.INDIACEM
Q2 24/251 Sep 2025 - Q3 FY25 saw lower revenue, major losses, UltraTech's takeover, and large asset revaluation gains.INDIACEM
Q3 24/251 Sep 2025